©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Biol Chem. May 26, 2015; 6(2): 16-27
Published online May 26, 2015. doi: 10.4331/wjbc.v6.i2.16
Published online May 26, 2015. doi: 10.4331/wjbc.v6.i2.16
Promise and challenges on the horizon of MET-targeted cancer therapeutics
Yu-Wen Zhang, Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI 49503, United States
Author contributions: Zhang YW solely contributed to this manuscript.
Conflict-of-interest: There is no potential conflict of interest relevant to this article.
Correspondence to: Yu-Wen Zhang, MD, PhD, Center for Cancer and Cell Biology, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503, United States. yuwen.zhang@vai.org
Telephone: +1-616-2345532 Fax: +1-616-2345533
Received: January 20, 2015
Peer-review started: January 20, 2015
First decision: February 7, 2015
Revised: April 8, 2015
Accepted: April 16, 2015
Article in press: April 18, 2015
Published online: May 26, 2015
Processing time: 121 Days and 13.4 Hours
Peer-review started: January 20, 2015
First decision: February 7, 2015
Revised: April 8, 2015
Accepted: April 16, 2015
Article in press: April 18, 2015
Published online: May 26, 2015
Processing time: 121 Days and 13.4 Hours
Core Tip
Core tip: Aberrant activation of MET receptor tyrosine kinase signaling is frequently observed in many human cancers. Such activation not only affects cancer development and progression, but it also contributes to resistance against other cancer drugs. The inhibition of MET signaling is an attractive approach for cancer intervention, and pursuit of MET-targeted cancer therapeutics is underway. Even though promising results have been reported from various clinical trials, many challenges remain to be addressed before and even after the arrival of such drugs in the clinic.